

Financial Highlights

		FY2009	FY2010	FY2011	FY2012	FY2013	Standardizing the Company's business year FY2013 1Q(Apr-Jun) <unaudited>	Standardizing the Company's business year FY2014 1Q(Apr-Jun)	Estimate FY2014 (Apr-Sep) Standardizing the Company's business year	Estimate FY2014 (Apr-Dec) Standardizing the Company's business year
Net sales	(Billions of yen)	1,084.3	1,127.6	1,154.6	1,218.1	1,452.8	354.8	386.3	795.0	1,200.0
	YoY	13.4%	4.0%	2.4%	5.5%	19.3%	-	8.9%	8.6%	5.8%
Operating income	(Billions of yen)	98.5	126.3	148.7	169.7	198.7	54.7	65.6	120.0	190.0
	YoY	7.6%	28.2%	17.7%	14.1%	17.1%	-	19.9%	6.0%	3.8%
Ordinary income	(Billions of yen)	109.1	128.4	152.1	184.5	215.2	62.8	69.5	125.0	195.0
	YoY	13.5%	17.7%	18.5%	21.3%	16.7%	-	10.6%	0.5%	-2.3%
Net income	(Billions of yen)	67.4	82.4	92.2	122.4	151.0	42.6	45.2	83.0	130.0
	YoY	43.2%	22.1%	11.9%	32.8%	23.3%	-	6.3%	-6.2%	-6.7%
R&D expenses	(Billions of yen)	151.8	164.7	159.2	192.4	249.0	51.0	50.1	117.0	180.0
	YoY	11.7%	8.4%	-3.3%	20.8%	29.4%	-	-1.7%	10.4%	6.1%
Overseas net sales	(Billions of yen)	525.5	552.5	579.7	622.7	824.4	198.7	237.6	459.0	700.0
	% of net sales	48.4%	49.0%	50.2%	51.1%	56.8%	56.0%	61.5%	57.7%	58.3%

(Yen)

Exchange rate (Yen)	FY2009	FY2010	FY2011	FY2012	FY2013	Standardizing the Company's business year FY2013 1Q(Apr-Jun) <unaudited>	Standardizing the Company's business year FY2014 1Q(Apr-Jun)	FY2014
US\$	92.10	87.79	79.79	79.80	97.72	98.77	102.16	100.00
Euro	132.00	116.27	111.12	102.55	129.77	128.95	140.07	140.00

(Billions of yen)

Selling, general and administrative expenses	FY2009	FY2010	FY2011	FY2012	FY2013	Standardizing the Company's business year FY2013 1Q(Apr-Jun) <unaudited>	Standardizing the Company's business year FY2014 1Q(Apr-Jun)	Estimate FY2014 (Apr-Sep) Standardizing the Company's business year	Estimate FY2014 (Apr-Dec) Standardizing the Company's business year
Selling, general and administrative expenses	629.2	622.3	616.6	654.6	812.4	191.6	207.7	433.0	650.0
(% of net sales)	58.0%	55.2%	53.4%	53.7%	55.9%	54.0%	53.8%	54.5%	54.2%
Promotion expenses	198.7	179.6	174.4	156.2	192.0	49.1	56.5		
Personnel expenses	96.7	97.9	99.8	103.7	124.0	30.8	32.2		
Advertising expenses	33.2	28.9	25.1	29.5	34.2	9.7	8.7		
R&D expenses	151.8	164.7	159.2	192.4	249.0	51.0	50.1	117.0	180.0
(% of net sales)	14.0%	14.6%	13.8%	15.8%	17.1%	14.4%	13.0%	14.7%	15.0%
R&D expenses of pharmaceutical business	141.6	153.4	149.3	183.5	240.8	49.0	48.1	112.0	172.0

(Billions of yen)

Capital expenditures	FY2009	FY2010	FY2011	FY2012	FY2013	Standardizing the Company's business year FY2013 1Q(Apr-Jun) <unaudited>	Standardizing the Company's business year FY2014 1Q(Apr-Jun)	Estimate FY2014 (Apr-Sep) Standardizing the Company's business year	Estimate FY2014 (Apr-Dec) Standardizing the Company's business year
Capital expenditures	62.5	44.8	43.3	63.3	179.0	161.1	10.6	40.0	58.0

(Billions of yen)

Depreciation	FY2009	FY2010	FY2011	FY2012	FY2013	Standardizing the Company's business year FY2013 1Q(Apr-Jun) <unaudited>	Standardizing the Company's business year FY2014 1Q(Apr-Jun)	Estimate FY2014 (Apr-Sep) Standardizing the Company's business year	Estimate FY2014 (Apr-Dec) Standardizing the Company's business year
Depreciation	46.6	48.1	48.1	45.5	49.8	12.0	14.6	23.0	34.0

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

Sales to Customers by Market

(Billions of yen)

Net sales by business segment	FY2009	FY2010	FY2011	FY2012	FY2013	Standardizing the Company's business year FY2013 1Q(Apr-Jun) <unaudited>	Standardizing the Company's business year FY2014 1Q(Apr-Jun)	Change
Consolidated sales	1,084.3	1,127.6	1,154.6	1,218.1	1,452.8	354.8	386.3	8.9%
Pharmaceutical business	715.9	751.1	782.2	850.9	1,035.1	243.7	275.4	13.0%
Japan	312.4	319.9	326.5	351.8	372.9	88.9	83.0	-6.7%
North America	334.7	349.0	361.1	389.0	530.5	124.4	153.5	23.4%
Others	68.8	82.2	94.7	110.0	131.7	30.4	38.9	27.9%
Nutraceutical business	247.0	256.4	251.3	246.9	281.1	77.4	75.3	-2.7%
Japan	142.6	154.1	147.4	142.3	147.5	40.8	37.8	-7.2%
North America	47.1	46.8	45.8	49.8	59.8	15.1	14.1	-6.5%
Others	57.3	55.6	58.1	54.8	73.9	21.6	23.4	8.4%
Consumer products business	50.1	47.1	48.0	45.2	43.8	11.5	11.8	2.7%
Japan	44.1	40.9	42.0	39.2	36.6	9.5	9.7	2.0%
North America	5.4	5.5	5.4	5.4	6.9	1.9	2.0	4.3%
Others	0.6	0.7	0.6	0.6	0.3	0.1	0.2	29.0%
Other business	71.3	72.9	73.1	75.0	92.8	22.2	23.8	7.5%
Japan	59.7	60.1	59.1	62.0	71.4	16.9	18.2	7.8%
North America	1.3	1.4	1.3	1.4	2.3	0.5	0.6	2.8%
Others	10.4	11.4	12.7	11.6	19.0	4.7	5.0	6.9%
Japan -total	558.8	575.1	574.9	595.3	628.3	156.1	148.7	-4.7%
North America - total	388.4	402.7	413.5	445.7	599.6	141.9	170.2	19.9%
Others - total	137.1	149.8	166.2	177.1	224.9	56.8	67.5	18.8%
Overseas net sales	525.5	552.5	579.7	622.7	824.4	198.7	237.6	19.6%
Overseas net sales ratio	48.4%	49.0%	50.2%	51.1%	56.8%	56.0%	61.5%	19.6%

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

Net Sales and Operating Income by Geographical and Business Segment

(1) Geographical segment

(Billions of yen)

	FY2009	FY2010	FY2011	FY2012	FY2013	Standardizing the Company's business year FY2013 1Q(Apr-Jun) <unaudited>	Standardizing the Company's business year FY2014 1Q(Apr-Jun)	Change
Net sales	1,084.3	1,127.6	1,154.6	1,218.1	1,452.8	354.8	386.3	8.9%
Japan*	709.4	745.2	779.1	842.5	982.1	228.1	234.1	2.6%
North America*	406.2	426.0	437.5	474.1	652.1	167.1	187.2	12.0%
Others*	121.6	132.5	142.4	138.2	204.4	51.6	61.9	20.0%
Eliminations/corporate	-152.8	-176.2	-204.4	-236.7	-385.9	-92.1	-96.9	

*Intersegment sales are included.

(Billions of yen)

	FY2009	FY2010	FY2011	FY2012	FY2013	Standardizing the Company's business year FY2013 1Q(Apr-Jun) <unaudited>	Standardizing the Company's business year FY2014 1Q(Apr-Jun)	Change
Operating income	98.5	126.3	148.7	169.7	198.7	54.7	65.6	19.9%
Japan	86.5	106.3	142.5	160.8	217.5	49.9	55.2	10.6%
North America	11.3	12.2	14.4	16.2	-5.0	1.3	5.6	319.8%
Others	8.4	6.8	3.7	6.4	1.9	0.9	-0.2	-127.5%
Eliminations/corporate	-7.7	1.0	-12.0	-13.8	-15.7	2.5	5.0	

(2) Business segment

(Billions of yen)

	FY2009	FY2010	FY2011	FY2012	FY2013	Standardizing the Company's business year FY2013 1Q(Apr-Jun) <unaudited>	Standardizing the Company's business year FY2014 1Q(Apr-Jun)	Change
Net sales	1,084.3	1,127.6	1,154.6	1,218.1	1,452.8	354.8	386.3	8.9%
Pharmaceutical business*	715.9	751.1	782.2	850.9	1,035.1	243.7	275.4	13.0%
Nutraceutical business*	248.8	258.7	254.8	251.8	287.1	78.9	77.1	-2.3%
Consumer products business*	51.1	47.9	49.2	46.9	43.9	11.6	11.9	2.6%
Other business*	105.1	106.9	108.6	111.7	130.3	32.4	34.0	4.8%
Eliminations/corporate	-36.6	-37.0	-40.3	-43.1	-43.7	-11.7	-12.0	

*Intersegment sales are included.

(Billions of yen)

	FY2009	FY2010	FY2011	FY2012	FY2013	Standardizing the Company's business year FY2013 1Q(Apr-Jun) <unaudited>	Standardizing the Company's business year FY2014 1Q(Apr-Jun)	Change
Operating income	98.5	126.3	148.7	169.7	198.7	54.7	65.6	19.9%
Pharmaceutical business	132.9	142.8	168.5	187.9	212.8	54.4	65.7	20.8%
Nutraceutical business	2.3	18.4	22.1	21.4	25.4	10.7	8.5	-21.0%
Consumer products business	-8.4	-2.2	-2.3	-2.4	-2.2	-0.7	0.1	115.3%
Other business	4.4	4.4	1.9	3.9	7.2	2.1	2.0	-5.3%
Eliminations/corporate	-32.7	-37.1	-41.6	-41.0	-44.5	-11.7	-10.6	

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

【Pharmaceutical business】

(Billions of yen)

Product name	Company	FY2009	FY2010	FY2011	FY2012	FY2013	Standardizing the Company's business year FY2013 1Q(Apr-Jun) <unaudited>	Standardizing the Company's business year FY2014 1Q(Apr-Jun)	Change	Estimate FY2014 (Apr-Sep) Standardizing the Company's business year	Estimate FY2014 (Apr-Dec) Standardizing the Company's business year
Antipsychotic agent <i>ABILIFY</i>	Otsuka Pharmaceutical	374.5	392.6	411.6	438.5	575.7	142.6	160.7	12.6%	318.0	483.0
North America		305.6	308.3	316.1	336.1	455.5	115.7	133.1	15.1%	255.0	384.0
<US\$ million>		<3,303>	<3,512>	<3,960>	<4,208>	<4,659>	<1,170>	<1,302>	11.3%	<2,550>	<3,840>
Japan		18.8	23.0	24.8	28.6	34.4	7.8	6.1	-21.8%	18.0	29.0
Others		50.1	61.2	70.7	73.9	85.8	19.1	21.4	11.8%	45.0	70.0
Anti-platelet agent <i>Pletaal/Pletal</i>	Otsuka Pharmaceutical	51.5	53.2	50.3	45.8	44.2	12.0	8.9	-25.8%	19.0	28.0
Japan		45.4	46.5	44.1	40.1	36.8	10.1	7.1	-30.0%	15.0	22.0
Others		6.1	6.7	6.2	5.7	7.4	1.9	1.8	-3.8%	4.0	6.0
Anti-gastritis and anti-gastric ulcer agent <i>Mucosta</i>	Otsuka Pharmaceutical	37.1	30.7	28.7	23.0	22.0	5.7	4.3	-23.8%	9.0	13.5
Japan		34.5	27.8	26.0	20.5	18.8	4.9	3.5	-29.1%	7.0	11.0
Others		2.6	2.9	2.7	2.5	3.1	0.8	0.9	9.5%	2.0	2.5
Anti-metabolite <i>TS-1</i>	Taiho Pharmaceutical	37.3	37.1	36.5	37.0	37.4	9.5	8.3	-13.3%	16.0	25.0
Anti-metabolite <i>UFT</i>	Taiho Pharmaceutical	18.3	15.7	12.9	11.2	9.5	2.6	2.2	-15.9%	4.0	6.0
Reduced folic acid formulation <i>Uzel</i>	Taiho Pharmaceutical	15.2	14.1	12.7	13.2	11.9	3.1	2.4	-21.6%	5.5	8.5
Urinary incontinence / frequency treatment <i>P4 (BUP-4)</i>	Taiho Pharmaceutical	7.6	7.0	6.3	5.6	4.7	1.3	1.0	-23.3%	2.0	3.5
Oral nutrient for liver failure <i>Aminoleban EN</i>	Otsuka Pharmaceutical	6.4	6.5	6.1	5.7	5.5	1.4	1.3	-11.9%	2.5	4.0
Bronchodilator <i>Meptin</i>	Otsuka Pharmaceutical	5.9	6.1	5.7	5.2	4.9	1.2	1.0	-13.5%	2.0	3.5
H ₂ -receptor antagonist <i>Protecadin</i>	Taiho Pharmaceutical	5.1	5.8	6.3	5.9	5.0	1.3	1.0	-24.4%	2.0	3.5
5-HT ₂ receptor antagonist <i>Aloxi</i>	Taiho Pharmaceutical	4.3	7.9	10.0	11.0		2.6	2.6	-0.2%	6.0	9.0
Antineoplastic <i>Abraxane</i>	Taiho Pharmaceutical	1.1	3.2	3.7	8.8		1.7	2.5	41.9%	5.5	8.5
Antiepileptic <i>E Keppra</i>	Otsuka Pharmaceutical	0.8	4.8	10.5	15.8		3.6	3.6	0.4%	10.0	16.0
V ₂ -vasopressin receptor antagonist <i>Samsca</i>	Otsuka Pharmaceutical	0.6	3.2	6.7	12.8	21.0	4.8	6.2	30.1%	13.0	21.0
Anticancer <i>SPRYCEL</i> (collaboration with BMS)	Otsuka Pharmaceutical	2.0	8.0	7.6	12.0	26.1	6.5	6.6	1.9%	13.0	20.0
Antibiotic <i>Zosyn/Tazocin</i> (bulk supply)	Taiho Pharmaceutical	11.2	11.2	10.7	12.4	14.5	2.7	3.2	17.5%	7.5	11.0
Diagnostics -total	Otsuka Pharmaceutical	8.2	6.6	7.9	8.8	12.6	2.0	2.0	-0.3%	5.0	8.0
Parenteral nutrition (clinical nutrition) -total	Otsuka Pharmaceutical Factory	92.9	96.8	96.0	96.4	103.4	25.1	25.2	0.7%	53.5	83.0
Japan		83.0	87.6	88.6	88.8	91.6	22.5	21.0	-6.7%	44.0	68.0
Others		9.9	9.2	7.4	7.6	11.8	2.6	4.3	63.7%	9.5	15.0
Pharmaceutical business -total (excluding exports)	Japan	312.4	319.9	326.5	351.8	372.9	88.9	83.0	-6.7%	181.0	282.0
Pharmaceutical business -total	Total	715.9	751.1	782.2	850.9	1,035.1	243.7	275.4	13.0%	550.0	842.0
Milestone and upfront revenue			7.3	14.9	41.5	22.0	3.2	6.8	112.6%	14.0	21.0

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

【Neutraceuticals business】

(10 thousand cases)

Product name	Company	FY2009	FY2010	FY2011	FY2012	FY2013	Standardizing the	Standardizing the	Change
							Company's business year FY2013 1Q(Apr-Jun)	Company's business year FY2014 1Q(Apr-Jun)	
<i>Pocari Sweat</i> 1 case: 24 bottles, and other (10 thousand cases)	Otsuka Pharmaceutical								
Japan		2,624	3,234	2,912	2,709	2,860	820	706	-13.9%
Overseas		1,884	1,597	1,963	2,151	2,684	796	842	5.7%
<i>SOYJOY</i> 1 case: 48 bars (10 thousand cases)	Otsuka Pharmaceutical								
Japan		187	113	100	88	109	38	44	15.4%
Overseas		46	28	20	12	16	4	5	28.3%
<i>Oronamin C</i> 1 case: 50 bottles (10 thousand cases)	Otsuka Pharmaceutical	1,042	1,051	1,081	1,067	1,105	311	287	-7.6%
<i>Calorie Mate</i> 1 case: 4 bars×30, and other (10 thousand cases)	Otsuka Pharmaceutical	396	392	351	335	340	87	87	-0.7%
<i>Tiovita Drink</i> 1 case: 50 bottles (10 thousand cases)	Taiho Pharmaceutical	428	484	531	489	402	100	95	-5.0%
<i>Solmack</i> (10 thousand of bottles)	Taiho Pharmaceutical	1,591	1,571	1,579	1,588	1,479	362	352	-2.7%

* Overseas sales include sales of consolidated subsidiaries only.

【Consumer business】

(10 thousand cases)

Product name	Company	FY2009	FY2010	FY2011	FY2012	FY2013	Standardizing the	Standardizing the	Change
							Company's business year FY2013 1Q(Apr-Jun)	Company's business year FY2014 1Q(Apr-Jun)	
<i>Bottled Water</i> 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	840	674	679	567	580	176	141	-19.8%
<i>NESCAFE</i> 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	676	680	616	536	448	114	92	-19.6%
<i>Match</i> 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	332	371	451	521	514	139	174	25.3%
<i>Other (tea drinks and other)</i> 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	390	267	317	300	265	65	56	-14.6%

【Other business】

(Billions of yen)

Product name	Company	FY2009	FY2010	FY2011	FY2012	FY2013	Standardizing the	Standardizing the	Change
							Company's business year FY2013 1Q(Apr-Jun) <unaudited>	Company's business year FY2014 1Q(Apr-Jun)	
Functional chemicals	Otsuka Chemical	23.2	26.3	27.9	26.6	33.5	8.5	9.1	6.6%
Fine chemicals	Otsuka Chemical	13.7	12.4	9.3	10.2	10.1	2.3	2.2	-2.5%

Otsuka Group – Pipeline Information

(as of Jun 31, 2014)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
Central nervous system						
OPC-14597 <ABILIFY*> <Abilify Maintena*>: Depot injection	aripiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Schizophrenia / Depot injection	JP	Filed
				Autism / Oral	JP	Phase III
				Tourette's disorder / Tablet	US	Filed
				Bipolar I / Depot injection	JP, US, EU	Phase III
				Agitation associated with dementia of the Alzheimer's type / Oral	JP	Phase III
L059 <E Keppra>	levetiracetam	UCB	Anti-epileptic drug	Epilepsy (generalized onset seizures) / Oral	JP	Phase III
				Epilepsy (partial onset seizures) / injection	JP	Filed**
				Epilepsy (partial onset seizures/mono therapy) / Oral	JP	Filed
OPC-34712	brexpiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Adjunctive therapy for major depressive disorder / Oral	US, EU	Phase III**
				Schizophrenia / Oral	JP, US, EU	Phase III**
				ADHD (Adults) / Oral	US	Phase II
				Agitation associated with dementia of the Alzheimer's type / Oral	US, EU	Phase III
				Posttraumatic stress disorder (PTSD) / Oral	US, EU	Phase III
Lu AE58054		Lundbeck	selective serotonin 5-HT ₆ receptor antagonist	Alzheimer's disease / Oral	US, EU	Phase III
ASC-01	aripiprazole, sertraline	Otsuka Pharmaceutical	Dopamine partial agonist/Selective serotonin reuptake inhibitor	Major depressive disorder / Oral	JP, Asia	Phase III

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

*: Product names used outside Japan.

** : Events after June 30, 2014

<Events after June 30, 2014>

Levetiracetam injection / Epilepsy (partial onset seizures): approved on July in Japan

Levetiracetam injection / Epilepsy (partial onset seizures -monotherapy): filed on July in Japan

Brexpiprazole / Adjunctive therapy for major depressive disorder • Schizophrenia : filed on July in US

Otsuka Group – Pipeline Information

(as of Jun 31, 2014)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
Oncology						
ABI-007 <Abraxane>	paclitaxel protein-bound particles for injectable suspension	Celgene	Anti-cancer (nanoparticle)	Pancreatic cancer / Injection	JP	Filed
S-1 <TS-1> Japan, Korea <TEYSUNO*> EU <愛斯万*> China <愛斯萬*> Taiwan <TS-ONE*> Singapore	tegafur, gimeracil, oteracil	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Gastric cancer / Oral	US	Phase III
				Uterocervical cancer / Oral	JP, Asia	Phase III
				Hepatocellular carcinoma / Oral	JP	Phase III
				Renal cell carcinoma / Oral	JP	Phase II
TSU-68	orantinib	(Sugen)	Anti-cancer (Molecular-targeted drug)	Hepatocellular carcinoma / Oral	JP, Asia	Phase III
TAS-102 <Lonsurf>	trifluridine, tipiracil	Taiho Pharmaceutical	Anti-cancer	Colorectal cancer / Oral	JP, US, EU, Asia	Phase III
				SCLC / Oral	JP, EU	Phase II
TAS-118	tegafur, gimeracil, oteracil, folinate	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Pancreatic cancer / Oral	JP, Asia	Phase III
<SATIVEX*>	nabiximols	GW Pharmaceuticals	Cannabinoid (THC, CBD)	Cancer pain / Oral spray	US	Phase III
OCV-101		OncoTherapy Science	Therapeutic cancer vaccine	Pancreatic cancer / Injection	JP	Phase II
<SPRYCEL>	dasatinib	BMS	Anti-cancer (Molecular-targeted drug)	Pancreatic cancer / Oral	US, EU	Phase II
SGI-110		Astex	Anti-cancer	Ovarian cancer / Injection	US, EU	Phase II
				Hepatocellular carcinoma / Injection	US, EU	Phase II
				Acute myeloid leukemia, Myelodysplastic syndrome / Injection	US	Phase II
AT13387		Astex	Anti-cancer (Molecular-targeted drug)	Prostate cancer / Injection	US, EU	Phase II
				NSCLC / Injection	US, EU	Phase II
AT7519		Astex	Anti-cancer (Molecular-targeted drug)	Multiple myeloma / Injection	US	Phase II
ET-743	trabectedin	PharmaMar	Anti-cancer	Malignant soft tissue sarcoma / Injection	JP	Phase II
OPB-31121		Otsuka Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Anti-cancer / Oral	JP, Asia	Phase I
OPB-51602		Otsuka Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Anti-cancer / Oral	JP, US, Asia	Phase I
OPB-111077		Otsuka Pharmaceutical	Anti-cancer	Solid tumors / Oral	US, Asia	Phase I
OPB-111001		Otsuka Pharmaceutical	Anti-cancer	Solid tumors / Oral	EU	Phase I
TAS-114		Taiho Pharmaceutical	Anti-cancer (Antitumor enhancer)	Solid tumors / Oral	JP, US, EU	Phase I
TAS-115		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
TAS-116		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
OCV-501		Otsuka Pharmaceutical	WT1 targeted cancer vaccine	Secondary Prevention of elderly acute myeloid leukemia / Injection	JP, Asia	Phase II
OCV-C02		OncoTherapy Science	Therapeutic cancer vaccine	Colorectal Cancer / Injection	JP	Phase I
OPC-12759	rebamipide	Otsuka Pharmaceutical	Oral mucosal protectant • mucosal healing agent	Stomatitis associated with cancer chemoradiotherapy / Solution	JP	Phase II

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.
*: Product names used outside Japan.

Otsuka Group – Pipeline Information

(as of Jun 31, 2014)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
Cardiovascular						
OPC-41061 <SAMSCA>	tolvaptan	Otsuka Pharmaceutical	Vasopressin V ₂ -receptor antagonist	Hepatic edema / Oral	Asia	Filed
				Autosomal dominant polycystic kidney disease / Oral	EU US	Filed Phase III
				Cardiac edema / Oral	Asia	Filed
				Carcinomatous edema / Oral	JP	Phase II
				Volume overload in hemodialysis / Oral	JP	Phase II
				Volume overload in peritoneal dialysis / Oral	JP	Phase II
OPC-108459		Otsuka Pharmaceutical		Paroxysmal and persistent atrial fibrillation / Injection	JP, US	Phase I
Other areas						
YP-18 <ZOSYN>	tazobactam, piperacillin	Taiho Pharmaceutical	Antibiotic agent	Febrile neutropenia / Injection	JP	Phase III**
TAC-202	bilastine	Faes Farma	Histamine H ₁ antagonist	Allergic rhinitis / Oral	JP	Phase II
				Chronic urticaria, Pruritus associated with skin disease/ Oral	JP	Phase II / III
OPC-67683 <Delyba>	delamanid	Otsuka Pharmaceutical	Anti-tuberculosis agent	Multidrug-resistant tuberculosis / Oral	EU JP US	Approved Filed** Phase III
				Multidrug-resistant tuberculosis for pediatrics / Oral	EU	Phase II
OPC-12759E <Mucosta Ophthalmic Suspension>	rebamipide	Otsuka Pharmaceutical	Mucin-production enhancing agent	Dry eyes / Eye drops MD (Multi Dose)	JP	Phase III
OPB-2045G	olanexidin	Otsuka Pharmaceutical Factory	Anti-septics	Patient preoperative preparation / Topical	JP	Filed
OPF-105	Amino Acid, Carbohydrate, and Fat Emulsion Injection with Electrolytes and Vitamins	Otsuka Pharmaceutical Factory	Protein and amino acid preparation	Peripheral parenteral nutrition solution / Injection	JP	Phase III
OPC-6535	tetomilast	Otsuka Pharmaceutical	Anti-inflammatory agent	COPD / Oral	JP, US, Asia	Phase II
ACU-4429	emixustat	Acucela	Visual cycle modulator	Dry AMD / Oral	US	Phase II b / III
OPA-6566		Otsuka Pharmaceutical	Adenosine A _{2a} receptor agonist	Glaucoma / Eye Drops	US	Phase I / II
OPC-1085EL	carteolol, latanoprost	Otsuka Pharmaceutical	β -adrenergic receptor blocker/ prostaglandine F ₂ α analogue	Glaucoma / Eye Drops	JP	Phase III
OPA-15406		Otsuka Pharmaceutical	PDE4 inhibitor	Atopic Dermatitis / Ointment	US	Phase II
Diagnostics						
C13-URA	Uracil (2-13C)	Otsuka Pharmaceutical	13C-uracil breath test	For the diagnosis of gastric emptying disorders / In-vivo diagnostic drug	US	Phase II
ODK-1201-01	Major bcr-abl mRNA kit	Otsuka Pharmaceutical	Diagnostic aid for CML	For the diagnosis of bcr-abl / In-vitro diagnostic agent	JP	Filed

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

*: Product names used outside Japan.

** : Events after June 30, 2014

<Events after June 30, 2014>

Tazobactam • Piperacillin injection/ Febrile neutropenia: filed on July in Japan

Delamanid / Multidrug-resistant tuberculosis: approved on July in Japan